| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,980,000 |
| Market
Cap: |
93.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.11 - $38 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,250 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
195,758 |
319,893 |
855,039 |
855,039 |
| Total Sell Value |
$681,109 |
$2,186,626 |
$14,794,739 |
$14,794,739 |
| Total People Sold |
1 |
4 |
11 |
11 |
| Total Sell Transactions |
10 |
17 |
54 |
54 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Szalay Aladar |
10% Owner |
– – • |
2023-09-11 |
4 |
S |
$21.39 |
$718,702 |
I/I |
(32,351) |
99,865 |
|
46% |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2023-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
12,065 |
|
- |
|
| Jewett Caroline |
Head of Quality |
• – – |
2023-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
21,135 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-08 |
4 |
S |
$22.78 |
$575,332 |
I/I |
(24,831) |
132,216 |
|
45% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-07 |
4 |
S |
$24.12 |
$303,268 |
I/I |
(12,446) |
157,047 |
|
45% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-08-30 |
4 |
S |
$24.70 |
$489,060 |
D/D |
(19,800) |
135,935 |
|
43% |
|
| Zindrick Thomas |
President and CEO |
• • – |
2023-08-18 |
4 |
S |
$23.73 |
$198,122 |
D/D |
(8,349) |
14,651 |
|
39% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$77,478 |
D/D |
(3,265) |
155,735 |
|
39% |
|
| Ryder Sean |
General Counsel |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$7,783 |
D/D |
(328) |
572 |
|
39% |
|
| Smalling Ralph |
Head of Regulatory |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$22,188 |
D/D |
(935) |
2,065 |
|
39% |
|
| Samuelson Doug |
Chief Financial Officer |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$30,778 |
D/D |
(1,297) |
2,303 |
|
39% |
|
| Jewett Caroline |
Head of Quality |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$12,221 |
D/D |
(515) |
1,135 |
|
39% |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$77,478 |
D/D |
(3,265) |
5,735 |
|
39% |
|
| Smalling Ralph |
Head of RegulatoryOfficer |
• – – |
2023-06-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,000 |
|
-56% |
|
| Jewett Caroline |
Head of QualityOfficer |
• – – |
2023-06-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,650 |
|
-56% |
|
| Zindrick Thomas |
President and CEO |
• • – |
2023-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
23,000 |
|
- |
|
| Thomas John |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
479,000 |
|
- |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
159,000 |
|
- |
|
| Tyree James L |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Samuelson Doug |
Chief Financial Officer |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Zhang Qian |
Associate VP, Research |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
139,333 |
|
- |
|
| Cappello Joseph |
VP, Pharmaceutical Development |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Mirabelli Mary |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
1,000 |
|
- |
|
| Woodward Gabe |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,186 |
|
- |
|
| Ryder Sean |
General Counsel |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
900 |
900 |
|
- |
|
84 Records found
|
|
Page 3 of 4 |
|
|
0.22 (5.74%) 
